Dallas, TX – January 12, 2017 – Puration, Inc. (USOTC: PURA) today announced plans for the official launch its EVERx Cannabinoil (CBD) Infused Water at a major industry trade show in March 2017. Working with Alkame Holdings’ (USOTC: ALKM) wholly owned subsidiary Xtreme Technologies, PURA has developed the EVERx CBD Infused Sports Drink with 10 mg of CBD in a 16.9 oz bottle. PURA will release the trade show details in early February. The trade show launch will be combined with the announcement of a notable sports figure spokesman for the EVERx brand. Based on an existing EVERx pre-order and the first distribution agreement, PURA anticipates $1 million in EVERx sales in 2017. PURA has published a comprehensive $3 million first year revenue plan for its overall product line.
PURA Proprietary CBD Extract and ALKM Water Technology
PURA’s proprietary CBD extract process is combined with ALKM’s patented technology that alters the structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. The ALKM technology breaks down the hydrogen bonds, reducing water's cluster size, providing a more efficient delivery system for the CBD. Separate from the infused CBD, the ALKM technology includes an optimal alkaline pH level formulated with antioxidants and electrolytes for effective hydration.
EVERx CBD Infused Water Target Market
EVERx will target the growing number of recreational and competitive athletes citing CBD for its benefits in substantially reducing recovery times and increasing cardio output as well as accelerating the healing process from injury and preventing against future injury. EVERx will also target the general consumer that is becoming more aware of the antioxidant and neural- protective research backed benefits of CBD. Research has shown CBD to mitigate diabetes risk and reduce cancer cells among demonstrating other specific targeted uses.
CBD for Fitness and Wellness
CBD is an ideal component of a pre and post workout regime. CBD works as an anti-inflammatory and relieves muscle spasms. CBD also works to relieve pain. CBD protects the heart, lungs and brain. Often essential when it comes to high intensity and competitive training, CBD reduces nausea, increases appetite and aides sleep. Ongoing research continues in regard to CBD as a treatment for sports related head trauma. CBD is not just a good addition to an athletes training regime; It can be the foundation of a healthy wellness routine for everyone.
CBD Water and the North American Cannabis Holdings (USMJ) EVERx Brand
PURA’s EVERx CBD Infused Water is one of an overall line of planned products under the EVERx brand name. The EVERx brand is owned by PURA’s partner North American Cannabis Holdings, Inc. (USOTC: USMJ). Last year, USMJ introduced the EVERx Sports and Fitness Nutritional Supplement Brand Name. PURA has entered into an agreement with USMJ to develop, market and sell a CBD Infused Water in a campaign designed to complement USMJ’s comprehensive EVERx brand.
$279.65 Billion Bottled Water Market
The bottled water market was valued at US $157.27 billion in 2013 and is expected to reach US $279.65 billion by 2020 (Transparency Market Research). Given the magnitude of the bottled water market, management plans to review first quarter performance and potentially increase the first year target at that time.
To learn more about North American Cannabis Holdings: growusmj.com.
Follow the Company on Twitter: US_HEMP
To learn more about Puration: purationinc.com
Follow Puration on Twitter: Puration710
Visit Puration on Facebook: Facebook.com/puration/
To learn more about Alamke Holdings, Inc.: alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO